A Real-World Study Comparing Various Antimicrobial Regimens for Bloodstream Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli in a Tertiary Hospital, Shanghai, China, from 2010 to 2017

References

• World Health Organization. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter Baumannii and Pseudomonas Aeruginosa in Health Care Facilities. Geneva: World Health Organization; 2017.
   Google Scholar
• Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22(Suppl 1):S9–14. doi:10.1016/j.cmi.2016.01.00127000156
   PubMed Web of Science ®Google Scholar
• Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17(8):1135–1141. doi:10.1111/j.1469-0691.2011.03553.x21635663
   PubMed Web of Science ®Google Scholar
• Giannella M, Trecarichi EM, Giacobbe DR, et al. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2018;51(2):244–248. doi:10.1016/j.ijantimicag.2017.08.01928842283
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8(12):751–762. doi:10.1016/S1473-3099(08)70279-219022191
   PubMed Web of Science ®Google Scholar
• Adnan S, Paterson DL, Lipman J, Roberts JA. Ampicillin/sulbactam: its potential use in treating infections in critically ill patients. Int J Antimicrob Agents. 2013;42(5):384–389. doi:10.1016/j.ijantimicag.2013.07.01224041466
   PubMed Web of Science ®Google Scholar
• Hagihara M, Housman ST, Nicolau DP, Kuti JL. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014;58(2):874–879. doi:10.1128/AAC.01624-1324277022
   PubMed Web of Science ®Google Scholar
• Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014;20(2):O117–23. doi:10.1111/1469-0691.1234123992130
   PubMed Web of Science ®Google Scholar
• Guan X, He L, Hu B, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect. 2016;22(Suppl 1):S15–25. doi:10.1016/j.cmi.2015.11.00426627340
   PubMed Web of Science ®Google Scholar
• Chang YY, Chuang YC, Siu LK, et al. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan. J Microbiol Immunol Infect. 2015;48(2):219–225. doi:10.1016/j.jmii.2014.05.01025074627
   PubMedGoogle Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829. doi:10.1097/00003246-198510000-000093928249
   PubMed Web of Science ®Google Scholar
• Wayne PA. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100; 2019.
   Google Scholar
• Food and Drug Administration. Highlights of Prescribing Information Tygacil. Silver Spring, MD: Food and Drug Administration; 2015.
   Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi:10.1001/jama.2016.028726903338
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–93. doi:10.1093/cid/cir07321258094
   PubMed Web of Science ®Google Scholar
• Mazuski JE, Tessier JM, May AK, et al. The surgical infection society revised guidelines on the management of intra-abdominal infection. Surg Infect. 2017;18(1):1–76. doi:10.1089/sur.2016.261
   PubMed Web of Science ®Google Scholar
• Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS. The Sanford Guide to Antimicrobial Therapy, Antimicrobial Therapy. Inc, Sperryville, VA; 2010.
   Google Scholar
• Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682–707. doi:10.1128/CMR.05035-1123034326
   PubMed Web of Science ®Google Scholar
• Falagas ME, Tensarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20(7):1170–1175. doi:10.3201/eid2007.12100424959688
   PubMed Web of Science ®Google Scholar
• Zak-Doron Y, Benattar YD, Pfeffer I, et al. The association between empirical antibiotic treatment and mortality in severe infections caused by carbapenem-resistant Gram-negative bacteria: a prospective study. Clin Infect Dis. 2018;67(12):1815–1823. doi:10.1093/cid/ciy37129718143
   PubMed Web of Science ®Google Scholar
• Buehrle DJ, Shields RK, Clarke LG, Potoski BA, Clancy CJ, Nguyen MH. Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure. Antimicrob Agents Chemother. 2016;61(1):pii: e01243–16.
   Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56(4):2108–2113. doi:10.1128/AAC.06268-1122252816
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328. doi:10.1128/AAC.02166-1324514083
   PubMed Web of Science ®Google Scholar
• Ng TM, Teng CB, Lye DC, Apisarnthanarak A. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2014;35(1):49–55. doi:10.1086/67438724334798
   PubMed Web of Science ®Google Scholar
• Stratton CW. In vitro susceptibility testing versus in vivo effectiveness. Med Clin North Am. 2006;90(6):1077–1088. doi:10.1016/j.mcna.2006.07.00317116437
   PubMed Web of Science ®Google Scholar